0001493152-23-004899.txt : 20230214 0001493152-23-004899.hdr.sgml : 20230214 20230214161547 ACCESSION NUMBER: 0001493152-23-004899 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230211 FILED AS OF DATE: 20230214 DATE AS OF CHANGE: 20230214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Samuel George A. III CENTRAL INDEX KEY: 0001878732 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12830 FILM NUMBER: 23629512 MAIL ADDRESS: STREET 1: C/O LINEAGE CELL THERAPEUTICS, INC. STREET 2: 2173 SALK AVENUE, SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lineage Cell Therapeutics, Inc. CENTRAL INDEX KEY: 0000876343 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943127919 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2173 SALK AVENUE STREET 2: SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: 5105213390 MAIL ADDRESS: STREET 1: 2173 SALK AVENUE STREET 2: SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 FORMER COMPANY: FORMER CONFORMED NAME: BIOTIME INC DATE OF NAME CHANGE: 19930328 4 1 ownership.xml X0306 4 2023-02-11 0 0000876343 Lineage Cell Therapeutics, Inc. LCTX 0001878732 Samuel George A. III 2173 SALK AVENUE, SUITE 200 CARLSBAD CA 92008 0 1 0 0 General Counsel/Secretary Common Shares, no par value 2023-02-11 4 M 0 6076 A 6076 D Common Shares, no par value 2023-02-11 4 F 0 2478 1.35 D 3598 D Restricted Stock Units 0.00 2023-02-11 4 M 0 6076 0.00 D Common Shares 6076 18227 D Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,076 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter. /s/ Grant Harbert, as Attorney-in Fact 2023-02-14